Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33) - PubMed (original) (raw)
Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33)
W E Boertien et al. Diabetologia. 2013 Aug.
Abstract
Aim/hypothesis: Arginine vasopressin (AVP), the hormone important for maintaining fluid balance, has been shown to cause kidney damage in rodent models of diabetes. We investigated the potential role of AVP in the natural course of kidney function decline in diabetes in an epidemiological study.
Methods: Plasma copeptin, a surrogate for AVP, was measured in baseline samples from patients with type 2 diabetes treated in primary care and included in the Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) cohort.
Results: Samples from 1,328 patients were available; 349 were analysed separately because they used renin-angiotensin-aldosterone system inhibition (RAASi), which influences albumin/creatinine ratio (ACR) and estimated (e)GFR. In the other 979 patients (46% men, age 68 years [58-75], ACR 1.8 mg/mmol [0.9-5.7], eGFR 67 ± 14 ml min(-1) 1.73 m(-2)) baseline copeptin (5.3 pmol/l [3.2-9.5]) was significantly associated with log e [ACR] and eGFR, even after adjustment for sex, age and risk factors for kidney function decline (standardised [std] β 0.13, p < 0.001, std β -0.20, p < 0.001 respectively). Follow-up data were available for 756 patients (6.5 years [4.1-9.6]). Baseline copeptin was associated with increase in ACR (std β 0.09, p = 0.02), but lost significance after adjustment (std β 0.07, p = 0.08). Copeptin was associated with a decrease in eGFR after adjustment (std β -0.09, p = 0.03). The strength of the association of copeptin with change in eGFR was stronger than that of established risk factors for kidney function decline (e.g. BMI, HbA1c). In patients who used RAASi there was a significant association between baseline copeptin and ACR and eGFR, but not with change in ACR and eGFR.
Conclusions/interpretation: In patients with diabetes not using RAASi a higher baseline copeptin concentration is significantly associated with higher baseline ACR and lower eGFR values and with a decline in eGFR during follow-up. This last association is independent of, and stronger than, most traditional risk factors for kidney function decline.
Similar articles
- Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-31).
Riphagen IJ, Boertien WE, Alkhalaf A, Kleefstra N, Gansevoort RT, Groenier KH, van Hateren KJ, Struck J, Navis G, Bilo HJ, Bakker SJ. Riphagen IJ, et al. Diabetes Care. 2013 Oct;36(10):3201-7. doi: 10.2337/dc12-2165. Epub 2013 Jun 11. Diabetes Care. 2013. PMID: 23757433 Free PMC article. - Copeptin, a surrogate marker for arginine vasopressin, is associated with disease severity and progression in IgA nephropathy patients.
Zittema D, van den Brand JA, Bakker SJ, Wetzels JF, Gansevoort RT. Zittema D, et al. Nephrol Dial Transplant. 2017 Jan 1;32(suppl_1):i146-i153. doi: 10.1093/ndt/gfw391. Nephrol Dial Transplant. 2017. PMID: 28057871 - Copeptin Plasma Levels are Associated with Decline of Renal Function in Patients with Type 2 Diabetes Mellitus.
Villela-Torres ML, Higareda-Mendoza AE, Gómez-García A, Alvarez-Paredes AR, García-López E, Stenvikel P, Gu HF, Rashid-Qureshi A, Lindholm B, Alvarez-Aguilar C. Villela-Torres ML, et al. Arch Med Res. 2018 Jan;49(1):36-43. doi: 10.1016/j.arcmed.2018.04.002. Epub 2018 Apr 14. Arch Med Res. 2018. PMID: 29665969 - Prognostic Value of Copeptin in Chronic Kidney Disease: From General Population to End-Stage Renal Disease.
Golembiewska E, Machowska A, Stenvinkel P, Lindholm B. Golembiewska E, et al. Curr Protein Pept Sci. 2017;18(12):1232-1243. doi: 10.2174/1389203718666170717095301. Curr Protein Pept Sci. 2017. PMID: 28714397 Review. - Water intake keeps type 2 diabetes away? Focus on copeptin.
Muscogiuri G, Barrea L, Annunziata G, Vecchiarini M, Orio F, Di Somma C, Colao A, Savastano S. Muscogiuri G, et al. Endocrine. 2018 Nov;62(2):292-298. doi: 10.1007/s12020-018-1680-7. Epub 2018 Jul 19. Endocrine. 2018. PMID: 30027433 Review.
Cited by
- Approach to the Patient: "Utility of the Copeptin Assay".
Christ-Crain M, Refardt J, Winzeler B. Christ-Crain M, et al. J Clin Endocrinol Metab. 2022 May 17;107(6):1727-1738. doi: 10.1210/clinem/dgac070. J Clin Endocrinol Metab. 2022. PMID: 35137148 Free PMC article. - Pathophysiology of copeptin in kidney disease and hypertension.
Afsar B. Afsar B. Clin Hypertens. 2017 Jun 13;23:13. doi: 10.1186/s40885-017-0068-y. eCollection 2017. Clin Hypertens. 2017. PMID: 28638629 Free PMC article. Review. - Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes.
Potier L, Roussel R, Marre M, Bjornstad P, Cherney DZ, El Boustany R, Fumeron F, Venteclef N, Gautier JF, Hadjadj S, Mohammedi K, Velho G. Potier L, et al. Diabetes Care. 2019 Dec;42(12):2290-2297. doi: 10.2337/dc19-1062. Epub 2019 Oct 3. Diabetes Care. 2019. PMID: 31582427 Free PMC article. - Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes.
Velho G, Ragot S, El Boustany R, Saulnier PJ, Fraty M, Mohammedi K, Fumeron F, Potier L, Marre M, Hadjadj S, Roussel R. Velho G, et al. Cardiovasc Diabetol. 2018 Aug 2;17(1):110. doi: 10.1186/s12933-018-0753-5. Cardiovasc Diabetol. 2018. PMID: 30071874 Free PMC article. - Hydration for health hypothesis: a narrative review of supporting evidence.
Perrier ET, Armstrong LE, Bottin JH, Clark WF, Dolci A, Guelinckx I, Iroz A, Kavouras SA, Lang F, Lieberman HR, Melander O, Morin C, Seksek I, Stookey JD, Tack I, Vanhaecke T, Vecchio M, Péronnet F. Perrier ET, et al. Eur J Nutr. 2021 Apr;60(3):1167-1180. doi: 10.1007/s00394-020-02296-z. Epub 2020 Jul 6. Eur J Nutr. 2021. PMID: 32632658 Free PMC article. Review.
References
- Diabetes Res. 1992;20(3):73-85 - PubMed
- Diabetologia. 2012 Jul;55(7):1963-70 - PubMed
- J Clin Endocrinol Metab. 1976 Apr;42(4):613-20 - PubMed
- Hypertension. 1983 Mar-Apr;5(2 Pt 2):I129-38 - PubMed
- Ann Intern Med. 1999 Mar 16;130(6):461-70 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous